A US ban on Chinese biotech and clinical trial collaborations would return global pharmaceutical leadership to European pharmas and investors, slow American patient access to new medicines, and accelerate the US dependency that protectionism claims to prevent.

The U.S. biotechnology sector is an indispensable, strategic national asset. But what if we’re taking it for granted? Recent attempts to weaken IP protections for Covid-19 vaccines and to implement drug price controls threaten future U.S. leadership in biotechnology.